{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:42:05Z","timestamp":1793252525315,"version":"4.5.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Antibody-based therapies that inhibit pro-inflammatory cytokine signalling are commonly used in dermatology. Paradoxically, these biological agents may induce or exacerbate paradoxical reactions. Recently, it has been reported that the treatment of eczema with dupilumab can lead to the development of psoriasiform eruptions, which we called psoriasiform paradoxical reactions (P-PRs). Conversely, cases of eczematous paradoxical reactions (E-PRs) have also been described in patients with psoriasis treated with biologics. To summarise the case characteristics and disease features of phenotypic transition between psoriasis and eczematoid dermatitis, and to explore the mechanism or connection related to biological agents or patients\u2019 genetic characteristics, a systematic review was conducted for P-PRs in atopic dermatitis and E-PRs in patients with psoriasis treated with corresponding biological agents, respectively. We identified a series of P-PRs in 42 atopic dermatitis cases treated with dupilumab. The time to onset of P-PRs typically ranged from weeks to months, with a mean latency period of 22.65 weeks. Almost all patients presented with new-onset P-PRs. Simultaneously, we reviewed 22 articles reporting 51 patients with psoriasis with biological agent-induced E-PRs, which occurred on average at 24.47 weeks, 72.55% of them induced by IL-17A inhibitors. 48.98% (24\/49) of cases reported a positive personal history of atopy, which may suggest an increased risk of biological agent-induced paradoxical eruptions. Overall, the improvement or resolution upon discontinuation of the inciting biologics was relatively common, and further studies are needed to estimate the real prevalence and unveil the pathophysiological mechanisms of these paradoxical events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_871_22","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T01:47:09Z","timestamp":1715737629000},"page":"186-191","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Biologics-Induced Immunophenotypic Cross-Switching in Patients with Psoriasis and Atopic Dermatitis"],"prefix":"10.4103","volume":"68","author":[{"given":"Yanyan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20240829","first-page":"e14169","article-title":"Psoriasis onset under dupilumab treatment in two patients affected by atopic dermatitis and one patient affected by alopecia areata: Clinical and dermoscopic patterns","volume":"33","author":"D\u2019Ambra","year":"2020","journal-title":"Dermatol Ther"},{"key":"R2-9-20240829","doi-asserted-by":"crossref","first-page":"e13142","DOI":"10.1111\/dth.13142","article-title":"Occurrence of psoriasiform eruptions during dupilumab therapy for adult atopic dermatitis: A case series","volume":"32","author":"Napolitano","year":"2019","journal-title":"Dermatol Ther"},{"key":"R3-9-20240829","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13555-021-00505-z","article-title":"Efficacy and Safety of Dupilumab in Clinical Practice: One Year of Experience on 165 Adult Patients from a Tertiary Referral Centre","volume":"11","author":"Napolitano","year":"2021","journal-title":"Dermatol Ther (Heidelb"},{"key":"R4-9-20240829","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2133.2008.08514.x","article-title":"Psoriasis treatment with etanercept and efalizumab: Clinical strategies inflfluencing treatment outcome","volume":"158","author":"Driessen","year":"2008","journal-title":"Br J Dermatol"},{"key":"R5-9-20240829","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ajhg.2014.12.004","article-title":"Genomewide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms","volume":"96","author":"Baurecht","year":"2015","journal-title":"Am J Hum Genet"},{"key":"R6-9-20240829","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1346-8138.13622","article-title":"Effificacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J Dermatol"},{"key":"R7-9-20240829","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jdcr.2020.01.012","article-title":"Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis","volume":"6","author":"Varma","year":"2020","journal-title":"JAAD Case Rep"},{"key":"R8-9-20240829","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2014.11.015","article-title":"The translational revolution and use of biologics in patients with inflammatory skin diseases","volume":"135","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R9-9-20240829","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis","volume":"86","author":"Murphy","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R10-9-20240829","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/09546634.2016.1230173","article-title":"Eczema as an adverse effect of anti-TNF\u03b1 therapy in psoriasis and other Th1-mediated diseases: A review","volume":"28","author":"Nakamura","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"R11-9-20240829","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000235582","article-title":"Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving inflfliximab: A cohort study of 92 patients","volume":"219","author":"Esmailzadeh","year":"2009","journal-title":"Dermatology"},{"key":"R12-9-20240829","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jdcr.2017.11.026","article-title":"Concurrence of psoriasis vulgaris and atopic eczema in a single patient exhibiting different expression patterns of psoriatic autoantigens in the lesional skin","volume":"4","author":"Ono","year":"2018","journal-title":"JAAD Case Rep"},{"key":"R13-9-20240829","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/bjd.14607","article-title":"Is there a pathogenic role for IgE in psoriasis?","volume":"175","author":"Heeringa","year":"2016","journal-title":"Br J Dermatol"},{"key":"R14-9-20240829","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/jid.2010.175","article-title":"Interleukin-17A promotes IgE production in human B cells","volume":"130","author":"Milovanovic","year":"2010","journal-title":"J Invest Dermatol"},{"key":"R15-9-20240829","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bjd.14459","article-title":"IgE and Fc\u03b5RI are highly expressed on innate cells in psoriasis","volume":"175","author":"Yan","year":"2016","journal-title":"Br J Dermatol"},{"key":"R16-9-20240829","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/ced.12086","article-title":"Serum IgE levels are increased in patients with generalized pustular psoriasis","volume":"38","author":"Ding","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"R17-9-20240829","first-page":"515","article-title":"Total serum IgE concentration in patients with psoriasis: A case-control study","volume":"52","author":"Lajevardi","year":"2014","journal-title":"Acta Med Iran"},{"key":"R18-9-20240829","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2021.05.013","article-title":"Development of psoriasis during treatment with dupilumab: A systematic review","volume":"86","author":"Brumfiel","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R19-9-20240829","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.0022-0477.2001.01250.x","article-title":"Coincidence of immune-mediated diseases driven by Th1 and Th2 subsets suggests a common aetiology. A population-based study using computerized general practice data","volume":"32","author":"Simpson","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"R20-9-20240829","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1093\/hmg\/ddt317","article-title":"A genome-wide association study of atopic dermatitis identifies loci with overlapping effect on asthma and psoriasis","volume":"22","author":"Weidinger","year":"2013","journal-title":"Hum Mol Genet"},{"key":"R21-9-20240829","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00105-010-2053-1","article-title":"Genetics of common chronic inflammatory skin diseases: An update on atopic dermatitis and psoriasis","volume":"62","author":"Rodr\u00edguez","year":"2011","journal-title":"Hautarzt"},{"key":"R22-9-20240829","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/exd.13336","article-title":"Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment","volume":"27","author":"Guttman-Yassky","year":"2018","journal-title":"Exp Dermatol"},{"key":"R23-9-20240829","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2500\/aap.2015.36.3808","article-title":"Serum interleukin 17, interleukin 23, and interleukin 10 values in children with atopic eczema\/dermatitis syndrome (AEDS): Association with clinical severity and phenotype","volume":"36","author":"Leonardi","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"R24-9-20240829","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic dermatitis and psoriasis: Two different immune diseases or one spectrum?","volume":"48","author":"Guttman-Yassky","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"R25-9-20240829","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/cod.12715","article-title":"Rapid allergen-induced interleukin-17 and interferon \u03b3 secretion by skin-resident memory CD8+T cells","volume":"76","author":"Schmidt","year":"2017","journal-title":"Contact Dermatitis"},{"key":"R26-9-20240829","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cod.12043","article-title":"CD4(+) T cells producing interleukin (IL)-17, IL-22 and interferon-\u03b3 are major effector T cells in nickel allergy","volume":"68","author":"Dyring-Andersen","year":"2013","journal-title":"Contact Dermatitis"},{"key":"R27-9-20240829","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.jid.2018.02.037","article-title":"IL-17C: A unique epithelial cytokine with potential for targeting across the spectrum of atopic dermatitis and psoriasis","volume":"138","author":"Guttman-Yassky","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R28-9-20240829","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ni.2156","article-title":"IL-17C regulates the innate immune function of epithelial cells in an autocrine manner","volume":"12","author":"Ramirez-Carrozzi","year":"2011","journal-title":"Nat Immunol"},{"key":"R29-9-20240829","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.jid.2018.01.036","article-title":"Neutralization of IL-17C reduces skin inflammation in mouse models of psoriasis and atopic dermatitis","volume":"138","author":"Vandeghinste","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R30-9-20240829","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1111\/jdv.15156","article-title":"Paradoxical eczematous reaction to ixekizumab","volume":"33","author":"Munera-Campos","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R31-9-20240829","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/1346-8138.16586","article-title":"Skin microbiome analysis in a case of atopic dermatitis induced by an interleukin 17 inhibitor used to treat psoriasis","volume":"50","author":"Hattori","year":"2023","journal-title":"J Dermatol"},{"key":"R32-9-20240829","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bjd.17779","article-title":"Eczematous eruptions during anti-interleukin 17 treatment of psoriasis: An emerging condition","volume":"181","author":"Napolitano","year":"2019","journal-title":"Br J Dermatol"},{"key":"R33-9-20240829","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jid.2017.12.024","article-title":"Unopposed IL-36 activity promotes clonal CD4+T-cell responses with IL-17A production in generalized pustular psoriasis","volume":"138","author":"Arakawa","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R34-9-20240829","doi-asserted-by":"crossref","first-page":"15631","DOI":"10.1038\/s41598-017-15892-7","article-title":"The psoriasisassociated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function","volume":"7","author":"Pfaff","year":"2017","journal-title":"Sci Rep"},{"key":"R35-9-20240829","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bjd.20064","article-title":"Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: A case report","volume":"185","author":"Mirza","year":"2021","journal-title":"Br J Dermatol"},{"key":"R36-9-20240829","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.jaad.2021.06.893","article-title":"Comment on: Development of psoriasis during treatment with dupilumab: A systematic review","volume":"86","author":"Cohen","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R37-9-20240829","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bjd.19459","article-title":"Increased expression of IL-23A in lesional skin of atopic dermatitis patients with psoriasiform reaction during dupilumab treatment","volume":"184","author":"Napolitano","year":"2021","journal-title":"Br J Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_871_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:35:09Z","timestamp":1787769309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_871_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_871_22","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}